MediMabBio antibody discovery I-O platform brings the advantages of rational drug design to
the large molecule therapeutic development. Following are the areas of our research:
Integration of high-quality computational datasets and structural modelling for precise targeting
De novo design and selection of antibody leads with optimized functionality, safety and developability criteria
Establishment and use of cancer patients-derived HMNC/TIL screening system for bringing better therapeutic development plans
Development of neokine-tethered-antibody fusion platform for targeting difficult-to-treat-cancers
Copyright © 2020 MEDIMABBIO All rights reserved.